Literature DB >> 18047002

Wavefront- versus topography-guided customized ablations with the NIDEK EC-5000 CX II in surface ablation treatment: refractive and aberrometric outcomes.

Paolo Vinciguerra1, Elena Albè, Fabrizio I Camesasca, Silvia Trazza, Daniel Epstein.   

Abstract

PURPOSE: To compare the long-term refractive outcomes and changes in higher order wavefront aberrations in patients undergoing photorefractive keratectomy (PRK) with topography-guided (CATz) or wavefront-guided (OPDCAT) ablation algorithm using the NIDEK Advanced Vision Excimer Laser System (NAVEX).
METHODS: A retrospective 12-month follow-up study was conducted of 226 eyes undergoing PRK. The NIDEK EC-5000 CX II excimer laser and Final Fit 1.11 treatment planning software were used. Sixty-eight eyes underwent OPDCAT ablation and 158 eyes underwent CATz ablation. Mean preoperative manifest refractive spherical equivalent (MRSE) was -5.73 +/- 2.03 diopters (D) (range: -11.25 to -2.50 D) in the OPDCAT group and -3.77 +/- 3.78 D (range: -12.50 to -5.75 D) in the CATz group.
RESULTS: At 12 months postoperatively, mean MRSE was 0.05 D for the OPDCAT group and plano for the CATz group. Stability was similar in both groups as were visual outcomes. No eyes lost 2 or more lines of BSCVA at 6 months postoperatively or later. Mean ocular wavefront higher order aberrations at 3 months postoperatively were 0.44 +/- 0.17 microm for the OPDCAT group and 0.55 +/- 0.27 microm for the CATz group.
CONCLUSIONS: Refractive outcomes were equivalent between eyes that underwent PRK with wavefront-guided ablation and those that underwent topography-guided ablation.

Entities:  

Mesh:

Year:  2007        PMID: 18047002     DOI: 10.3928/1081-597X-20071102-09

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  8 in total

1.  Clinical outcomes between optical path difference custom aspheric treatment and optimized prolate ablation photorefractive keratectomy in myopia exceeding 8 diopters.

Authors:  B J Choi; Y M Park; J S Lee
Journal:  Eye (Lond)       Date:  2014-11-14       Impact factor: 3.775

2.  Three different aspheric treatment algorithms of laser-assisted sub-epithelial keratectomy in patients with high myopia.

Authors:  Ji Min Ahn; Bong Joon Choi; Eung Kweon Kim; Bradford Sgrignoli; Tae-im Kim
Journal:  Jpn J Ophthalmol       Date:  2012-12-07       Impact factor: 2.447

3.  Using LaserSight Astrapro Planner 2.2 Z software in corneal topography-guided laser in situ keratomileusis for myopia with asymmetric corneal shape.

Authors:  Bing Liu; Wei Chen; De-Wang Shao; Hua Wang; Hai-Xia Ru; Min Zhang; Ying Wang; Chun-Yan Yang
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

4.  Wavefront-guided laser in situ keratomileusis (Lasik) versus wavefront-guided photorefractive keratectomy (Prk): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis).

Authors:  Edward E Manche; Weldon W Haw
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

5.  Importance of fixation, pupil center, and reference axis in ocular wavefront sensing, videokeratography, and retinal image quality.

Authors:  Raymond A Applegate; Larry N Thibos; Michael D Twa; Edwin J Sarver
Journal:  J Cataract Refract Surg       Date:  2009-01       Impact factor: 3.351

6.  [Wavefront analysis in ophthalmologic diagnostics].

Authors:  M J Sanchez; A Mannsfeld; A F M Borkenstein; A Ehmer; I-J Limberger; M P Holzer; G U Auffarth
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

7.  One-step transepithelial topography-guided ablation in the treatment of myopic astigmatism.

Authors:  Aleksandar Stojanovic; Shihao Chen; Xiangjun Chen; Filip Stojanovic; Jia Zhang; Ting Zhang; Tor Paaske Utheim
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

8.  Wavefront-Guided Photorefractive Keratectomy with the Use of a New Hartmann-Shack Aberrometer in Patients with Myopia and Compound Myopic Astigmatism.

Authors:  Steven C Schallhorn; Jan A Venter; Stephen J Hannan; Keith A Hettinger
Journal:  J Ophthalmol       Date:  2015-10-04       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.